Wegovy vs Ozempic vs Zepbound vs Mounjaro: The GLP-1 Brand Name Cheat Sheet

The GLP-1 market in 2026 is a brand-name mess. Six products share three active ingredients between two manufacturers, and the brand names give no hint about which is which. Patients consistently search for “is Zepbound the same as Mounjaro” (yes), “is Wegovy the same as Ozempic” (almost), and “is Zepbound a semaglutide” (no — it's tirzepatide) at a combined ~5,800 monthly searches. This cheat sheet untangles all of it in one place, with the FDA indications and dosing pulled directly from each product's prescribing information.

The one-page summary

Is Wegovy the same as Ozempic?

Almost. Both Wegovy and Ozempic contain the same active ingredient — semaglutide — and are made by the same manufacturer, Novo Nordisk. Both are weekly subcutaneous injection pens. The differences are [1, 2]:

• Maximum dose. Wegovy goes up to 2.4 mg weekly (the weight-management dose). Ozempic goes up to 2.0 mg weekly (the diabetes dose).
• FDA indication. Wegovy is approved for chronic weight management in adults and adolescents with obesity, plus cardiovascular risk reduction in adults with known heart disease and obesity. Ozempic is approved for type 2 diabetes, cardiovascular risk reduction in adults with T2D and heart disease, and — most recently — reducing the risk of kidney disease progression in adults with T2D + CKD (the FLOW trial indication, approved January 2025).
• Insurance coverage. Ozempic is covered by most insurance plans for T2D patients because it's a diabetes drug. Wegovy is frequently excluded from commercial plans because anti-obesity drug coverage is still a volatile category. This is the single biggest practical difference.
• Room-temperature storage window. Ozempic gets 56 days at room temperature after first use; Wegovy gets only 28 days. See our storage guide for the full FDA-label comparison.

In clinical effect they are essentially identical at equivalent doses. Patients sometimes find their insurance will cover Ozempic but not Wegovy even though a prescriber could achieve similar weight loss outcomes with either. This drives a lot of off-label Ozempic prescribing for weight loss — which is legal but complicated.

Is Zepbound the same as Mounjaro?

Yes — they are the same drug. Both contain tirzepatide, are manufactured by Eli Lilly, and are weekly subcutaneous injection pens. The only differences [4, 5]:

• FDA indication. Zepbound is approved for chronic weight management and obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes. Same molecule, two labels.
• Insurance coverage. Like Ozempic vs Wegovy, Mounjaro is covered for diabetes patients while Zepbound coverage for weight management is inconsistent across commercial plans.
• Packaging. Different pen colors and different pharmacy labels, but the active drug inside is identical.

If you are asking “should I use Zepbound or Mounjaro?” the honest answer is “it depends on what your insurance covers and what your prescriber writes. The drug is the same.”

Is Zepbound a semaglutide? Is Wegovy a tirzepatide?

No. This is the most confused GLP-1 brand question on Google:

• Zepbound is tirzepatide, not semaglutide. Tirzepatide is a dual GLP-1 + GIP receptor agonist made by Eli Lilly. Semaglutide is a single GLP-1 receptor agonist made by Novo Nordisk. Different molecules, different manufacturers.
• Wegovy is semaglutide, not tirzepatide. Same molecule as Ozempic and Rybelsus, different brand and indication.

The quickest way to remember: if the brand starts with W or O, it's Novo Nordisk's semaglutide. If the brand starts with Z or M, it's Eli Lilly's tirzepatide. If it's Rybelsus, it's oral semaglutide. If it's Foundayo, it's the new oral non-peptide orforglipron.

What is Rybelsus?

Rybelsus is oral semaglutide — the same active ingredient as Wegovy and Ozempic, but formulated as a daily pill rather than a weekly injection [3]. To survive stomach acid, Rybelsus uses a special absorption enhancer (SNAC) and must be taken on an empty stomach with no more than 4 ounces of water, then the patient must wait 30 minutes before eating, drinking, or taking other oral medications.

Rybelsus is FDA-approved for type 2 diabetes only. It is not approved for weight management. The practical constraint of the empty-stomach-plus-30-minute-wait rule has limited its uptake compared to injectable semaglutide.

What is Foundayo?

Foundayo (orforglipron) is the newest entry in the category — FDA-approved on April 1, 2026 [6]. It is the first non-peptide small-molecule GLP-1 receptor agonist approved for chronic weight management. Unlike Rybelsus (which is still a peptide and requires empty-stomach dosing), Foundayo is a true small molecule that can be taken any time of day with or without food.

Foundayo is made by Eli Lilly and is positioned between the injectable drugs and the older oral semaglutide in the market. See our Foundayo approval deep-dive for the full ATTAIN-1 trial data and the $25-$149/month launch pricing.

Generic vs compounded vs brand-name

All of the above are brand-name products — the FDA-approved, manufacturer-labeled versions sold through pharmacies at brand pricing. A separate market exists for compounded semaglutide and tirzepatide, which are prepared by 503A and 503B compounding pharmacies from the same active pharmaceutical ingredients but are not FDA-approved as finished products.

Compounded GLP-1s are sold primarily through telehealth providers at significantly lower cash prices than the brand names. They ship in vials rather than pens, and the patient draws their own dose with an insulin syringe. They are not generics — a generic is an exact copy of a brand-name drug that the FDA has approved as bioequivalent, and no such generics exist for these drugs. For the distinction and the quality considerations, see our compounded semaglutide bioequivalence investigation, our PCAB accreditation guide, and our Wegovy pen vs compounded vial deep-dive.

Which drug should I ask my prescriber about?

For most adult patients with obesity and no diabetes, the current decision tree looks roughly like this:

1. If insurance covers it: Wegovy (larger data package for weight management) or Zepbound (larger effect size in head-to-head trial comparisons). Zepbound wins on effect size; Wegovy wins on cardiovascular outcomes data (SELECT).
2. If you have type 2 diabetes: Ozempic or Mounjaro (insurance coverage is almost universal for T2D) with off-label weight management as a secondary benefit.
3. If cost is the primary constraint: Foundayo at $149/month self-pay (if the lower effect size is acceptable) or compounded semaglutide/tirzepatide (typically $150-$300/month).
4. If needle aversion is the issue: Foundayo (daily pill, no food restrictions) or Rybelsus (daily pill, strict food restrictions — less practical).

For the detailed comparison of effect sizes across all the approved drugs, see our tirzepatide vs semaglutide head-to-head.

Related research and tools

For the weight loss prediction at each drug scaled to your body weight, use our weight loss calculator. For the onset and steady-state timing, see our how long does GLP-1 take to work guide. For injection technique across all the pens, see our injection guide. For the Foundayo approval news, see our Foundayo deep-dive. For compounded vs brand comparison, see our pen vs compounded vial guide.